SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Organogenesis Holdings Inc. (ORGO) News

Track canonical SquawkNews coverage tagged to ORGO, Organogenesis Holdings Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol ORGO Asset equity Sector Markets 90 days 6 Last 1.395 Updated Aug 07, 2026, 12:02 PM UTC Open live news feed
H Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining over 100 points on Friday. Shares of Trade Desk Inc (NASDAQ: TTD ) fell sharply in pre-market trading after the company reported worse-than- EARNINGS | Aug 07, 2026, 12:02 PM UTC H Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket Shares of Atlassian Corp (NASDAQ: TEAM ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Atlassian reported fourth-quarter revenue of $1.766 billion, u EARNINGS | Aug 07, 2026, 08:33 AM UTC L Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est Organogenesis Holdings (NASDAQ: ORGO ) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate. EARNINGS | Aug 06, 2026, 08:16 PM UTC L ORGO Organogenesis announces publication of peer-reviewed clinical trial results demonstrating clinical benefit of affinity™ in the most cha ORGO Organogenesis announces publication of peer-reviewed clinical trial results demonstrating clinical benefit of affinity™ in the most challenging and complex venous leg ulcers EQUITY | Jul 27, 2026, 08:05 PM UTC H Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE: DHR ) fell sharply in pre-market trading following second-quarter results. Danaher p EARNINGS | Jul 21, 2026, 12:01 PM UTC L Organogenesis announces FDA acceptance of ReNu biologics license application Organogenesis announced that the FDA has completed their filing determination and accepted for review the company's biologics license application, or BLA, for ReNu, a cryopreserved, amniotic suspension allograft develope EQUITY | Jul 06, 2026, 08:08 PM UTC